studies

la/mBC - HR-positive - 2nd line (L2), mTOR inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsNCT02756364 (sapanisertib daily), 2022 0.77 [0.47; 1.26] 0.77[0.47; 1.26]NCT02756364 (sapanisertib daily), 202210%93NAnot evaluable CBRdetailed resultsNCT02756364 (sapanisertib daily), 2022 2.56 [0.94; 6.96] 2.56[0.94; 6.96]NCT02756364 (sapanisertib daily), 202210%93NAnot evaluable objective responses (ORR)detailed resultsNCT02756364 (sapanisertib daily), 2022 2.23 [0.68; 7.30] 2.23[0.68; 7.30]NCT02756364 (sapanisertib daily), 202210%93NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-04 14:41 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 711,507,1040,1434